rpl-13 Antibody

What is RPL13 and why is it significant in cellular research?

RPL13 (also called eL13) is a ribosomal protein that forms an essential component of the 60S ribosomal subunit. It plays a critical role in ribosome assembly and protein translation. The significance of RPL13 extends beyond basic ribosomal function, as it has been implicated in specific developmental processes. RPL13 is present at high levels in chondrocytes and osteoblasts in mouse growth plates, suggesting a specialized role in bone development . Recent research has identified RPL13 variants as causative factors in spondyloepimetaphyseal dysplasia with severe short stature, establishing RPL13 as a component of human ribosomopathies . Understanding RPL13 function is crucial for investigations into protein synthesis regulation, ribosome biogenesis, and specific developmental disorders.

What are the typical molecular characteristics of RPL13 protein that researchers should be aware of?

RPL13 has a calculated molecular weight of approximately 18-24 kDa, though it is typically observed at around 28 kDa in Western blot applications . This discrepancy between calculated and observed molecular weights is not uncommon for ribosomal proteins due to post-translational modifications or the inherent properties of these proteins during electrophoresis. The protein consists of 211 amino acids in humans, with a characteristic U-shaped architecture that is critical for its interactions with ribosomal RNA, particularly with Expansion Segment 7L (ES7L) of the 28S RNA . Researchers should note that RPL13 variants, such as those causing spondyloepimetaphyseal dysplasia, may contain additional amino acid insertions that can alter the molecular weight and potentially the antibody recognition pattern. For instance, variants with an 18-amino acid insertion resulting from partial intron retention would appear as a 26 kDa band in addition to the normal 24 kDa band on Western blots .

Which species reactivity can be expected when using commercial RPL13 antibodies?

Commercial RPL13 antibodies typically demonstrate reactivity with human, mouse, and rat samples . For example, the RPL13 polyclonal antibody from Abbexa (as indicated in search result 3) is specifically validated for these three species . Similarly, Proteintech's antibody (11271-1-AP) has been tested and confirmed to react with human, mouse, and rat samples . The antibody from Assay Genie (CAB4083) also demonstrates reactivity against human, mouse, and rat samples . When planning experiments involving other species, researchers should carefully review the documentation for each antibody or consider conducting preliminary validation studies to confirm cross-reactivity. The high conservation of ribosomal proteins across mammalian species suggests potential broader reactivity, but this should always be experimentally verified rather than assumed.

What are the validated applications for RPL13 antibodies in research protocols?

RPL13 antibodies have been validated for multiple research applications, providing versatility for investigating this ribosomal protein across different experimental contexts. Western blotting (WB) is the most commonly validated application, with working dilutions typically ranging from 1:200 to 1:2000, depending on the specific antibody . Immunohistochemistry on paraffin-embedded sections (IHC-P) is another validated application, with recommended dilutions between 1:20 and 1:200 . For IHC applications, antigen retrieval with TE buffer at pH 9.0 is often suggested, although citrate buffer at pH 6.0 can serve as an alternative . Immunofluorescence and immunocytochemistry (IF/ICC) applications are also supported by several commercial antibodies, with working dilutions generally in the range of 1:50 to 1:200 . Additionally, some antibodies have been validated for immunoprecipitation (IP), with recommendations to use 0.5-4.0 μg of antibody for 1.0-3.0 mg of total protein lysate . These applications enable researchers to examine RPL13 expression, localization, and interactions in diverse experimental settings.

How should researchers optimize Western blot protocols for detecting RPL13?

Optimization of Western blot protocols for RPL13 detection requires attention to several critical parameters. First, sample preparation should involve complete cell lysis using appropriate buffers such as RIPA buffer supplemented with protease inhibitors to prevent protein degradation . For total protein extraction, cells should be grown to approximately 90% confluence before lysis . Given RPL13's molecular weight of approximately 24 kDa (observed at 28 kDa in some cases), researchers should select an appropriate percentage acrylamide gel (12-15%) to achieve optimal separation in this molecular weight range .

Loading controls should be carefully selected; acetylated-tubulin has been successfully used as a loading control in published RPL13 Western blot protocols . For primary antibody incubation, dilutions ranging from 1:500 to 1:1000 are generally effective for RPL13 detection , though this should be optimized for each specific antibody and experimental system. Secondary antibody selection should match the host species of the primary antibody, with HRP-conjugated anti-mouse or anti-rabbit antibodies being commonly used at dilutions of approximately 1:20,000 . When analyzing RPL13 variants, researchers should be prepared to detect multiple bands representing wild-type and variant proteins, as demonstrated in studies of RPL13 variants associated with spondyloepimetaphyseal dysplasia, where both 24kDa and 26kDa bands were observed .

What are the best practices for immunohistochemical detection of RPL13 in different tissue types?

Successful immunohistochemical detection of RPL13 requires careful attention to tissue preparation, antigen retrieval, and antibody incubation conditions. For formalin-fixed, paraffin-embedded (FFPE) tissues, complete deparaffinization and rehydration are essential first steps. Antigen retrieval is particularly critical; for RPL13 detection, TE buffer at pH 9.0 is often recommended, although citrate buffer at pH 6.0 can be used as an alternative . The optimal antibody dilution for IHC applications typically ranges from 1:20 to 1:200, depending on the specific antibody and tissue type .

Different tissue types may require protocol modifications. For bone tissues, where RPL13 has particular relevance due to its role in spondyloepimetaphyseal dysplasia, decalcification procedures must be carefully selected to preserve antigenicity while allowing for effective sectioning. Commercial RPL13 antibodies have been successfully used to detect the protein in various tissues, including human colon cancer tissue and potentially in bone growth plates, where RPL13 is known to be highly expressed in chondrocytes and osteoblasts . Appropriate positive and negative controls should always be included; human colon cancer tissue has been validated as a positive control for some commercial antibodies . For detecting low-abundance RPL13 in certain tissues, signal amplification methods may be necessary, and background reduction strategies should be implemented, particularly when examining tissues with high autofluorescence or endogenous peroxidase activity.

How can RPL13 antibodies be used to investigate the molecular basis of ribosomopathies?

RPL13 antibodies offer powerful tools for investigating ribosomopathies, particularly the recently characterized spondyloepimetaphyseal dysplasia associated with RPL13 variants. Western blotting with RPL13 antibodies can detect both wild-type and variant proteins, as demonstrated in studies where two bands (24kDa and 26kDa) were observed in cells from affected individuals, compared to a single band in control cells . This differential banding pattern allows researchers to confirm the expression of variant proteins resulting from splicing mutations or other genetic alterations.

Immunofluorescence studies using RPL13 antibodies can examine the subcellular localization of wild-type versus variant RPL13 proteins, providing insights into potential disruptions in nucleolar localization or integration into ribosomal subunits. When combined with ribosome profiling techniques, such as sucrose gradient fractionation followed by Western blotting, RPL13 antibodies can determine whether variant proteins are successfully incorporated into mature ribosomes . This approach has revealed that certain RPL13 variants, despite containing an 18-amino acid insertion, are still incorporated into 60S subunits and translate-competent ribosomes .

For in-depth analysis of tissue-specific effects in ribosomopathies, immunohistochemistry with RPL13 antibodies can examine expression patterns in affected tissues, such as growth plate cartilage in spondyloepimetaphyseal dysplasia. This is particularly relevant given the high expression of RPL13 in chondrocytes and osteoblasts . Co-immunoprecipitation experiments using RPL13 antibodies can identify altered interactions between variant RPL13 proteins and other ribosomal components or regulatory factors, potentially revealing mechanisms underlying the tissue-specific manifestations of ribosomopathies despite the ubiquitous nature of ribosomal proteins.

What controls and validation steps are necessary when using RPL13 antibodies in critical research applications?

Rigorous validation of RPL13 antibodies is essential for ensuring reliable and reproducible research outcomes. Primary validation should include Western blotting on positive control samples with known RPL13 expression, such as HeLa cells, SGC-7901 cells, or human lung tissue, which have been confirmed to express detectable levels of RPL13 . Negative controls should include RPL13 knockdown samples generated using siRNA or shRNA approaches, as demonstrated in studies where siRNA-mediated depletion of RPL13 resulted in specific phenotypes that could be distinguished from those caused by RPL13 variants .

For antibody specificity validation, peptide competition assays can confirm that the observed signal is specifically due to RPL13 detection. This involves pre-incubating the antibody with an excess of the immunizing peptide before application to samples, which should eliminate specific binding. When working with tissues or cell types not previously tested with a particular RPL13 antibody, researchers should first confirm reactivity using multiple detection methods (e.g., Western blot and immunofluorescence).

In studies of RPL13 variants, controls should include samples from unaffected individuals alongside those from affected individuals. This is exemplified in research on RPL13-associated spondyloepimetaphyseal dysplasia, where Western blotting clearly distinguished between the single band pattern in control cells and the double band pattern in cells from affected individuals . For quantitative applications, standard curves using recombinant RPL13 protein can calibrate signal intensity to protein quantity. Additionally, multiple RPL13 antibodies targeting different epitopes can provide confirmation of results, particularly when studying variants that might affect antibody recognition at specific regions of the protein.

How do RPL13 variants affect ribosome structure and function, and how can this be studied using antibodies?

To study these structural implications, researchers can use RPL13 antibodies in combination with ribosome profiling techniques. Sucrose gradient fractionation followed by Western blotting with RPL13 antibodies has revealed that variant RPL13 proteins distribute in the gradient exactly as wild-type proteins, demonstrating their incorporation into 60S subunits capable of forming translation-competent ribosomes . This suggests that the structural alterations do not prevent ribosome assembly but may affect ribosome function more subtly.

Functional analyses have shown that while cells expressing RPL13 variants do not exhibit the severe pre-rRNA processing defects seen in RPL13-depleted cells, they do show alterations in the ribosome profile, particularly a decrease in 80S and polysome peaks . This indicates changes in translation dynamics rather than ribosome biogenesis. To further investigate these functional impacts, RPL13 antibodies can be used in polysome profiling experiments to examine the distribution of wild-type versus variant RPL13 across different translation states. Additionally, proximity labeling approaches combined with RPL13 antibodies for immunoprecipitation can identify altered interactions between variant RPL13 and other factors involved in translation, potentially revealing mechanisms for tissue-specific effects in conditions like spondyloepimetaphyseal dysplasia.

What are common challenges in RPL13 antibody applications and how can they be addressed?

Researchers working with RPL13 antibodies may encounter several challenges that require specific troubleshooting strategies. One common issue is weak or absent signal in Western blot applications, which can result from insufficient protein extraction or degradation of the target protein. To address this, optimization of lysis conditions is essential, including the use of RIPA buffer with protease inhibitors for complete cell lysis . For tissues with high RNase activity, additional RNase inhibitors may help preserve RPL13 associated with RNA.

Background issues in immunohistochemistry and immunofluorescence applications can obscure specific RPL13 detection. This can be mitigated by optimizing blocking conditions (typically 5% BSA or normal serum from the same species as the secondary antibody) and thorough washing steps. For tissues with high autofluorescence, such as bone samples relevant to RPL13-associated disorders, treatment with sodium borohydride or specialized autofluorescence quenching agents may be beneficial.

Specificity concerns may arise, particularly when detecting RPL13 variants alongside wild-type protein. Verification through multiple techniques is advisable, such as combining Western blot results with immunofluorescence or mass spectrometry. For studying RPL13 variants with small insertions (like the 18-amino acid insertion in spondyloepimetaphyseal dysplasia), higher-resolution SDS-PAGE systems may be needed to clearly distinguish the size difference between wild-type (24kDa) and variant (26kDa) proteins .

When investigating tissue-specific effects of RPL13, such as in growth plate cartilage, optimization of fixation and antigen retrieval methods is crucial, as overfixation can mask epitopes while insufficient fixation may compromise tissue morphology. Testing multiple antigen retrieval methods (heat-induced versus enzymatic) can help identify optimal conditions for specific tissue types.

How can RPL13 antibodies be employed to investigate translation dynamics in development and disease?

RPL13 antibodies offer valuable tools for examining translation dynamics in various developmental and disease contexts. Polysome profiling combined with Western blotting using RPL13 antibodies can reveal changes in the distribution of ribosomes across different translation states. This approach has demonstrated alterations in cells expressing RPL13 variants, specifically showing decreased 80S and polysome peaks despite normal incorporation of the variant protein into ribosomes .

For investigating tissue-specific translation patterns, immunohistochemistry with RPL13 antibodies can map expression in developing tissues, providing insights into areas of high translational activity. This is particularly relevant given the observed high expression of RPL13 in chondrocytes and osteoblasts of the growth plate, suggesting potential specialized roles in bone development . Dual immunofluorescence labeling with RPL13 antibodies alongside markers for specific cell types or cellular compartments can further elucidate the spatial regulation of translation.

In disease models, particularly those involving ribosomopathies, RPL13 antibodies can track changes in ribosome composition and distribution. For instance, in cells from individuals with spondyloepimetaphyseal dysplasia, while pre-rRNA processing appears normal (unlike in RPL13 knockdown cells), there are subtle changes in the ribosome profile that suggest altered translation dynamics . These changes might reflect specialized roles of RPL13 in translating specific mRNAs in affected tissues.

Advanced techniques like ribosome profiling coupled with immunoprecipitation using RPL13 antibodies (TRIP) could potentially identify mRNAs preferentially translated by ribosomes containing wild-type versus variant RPL13, providing mechanistic insights into tissue-specific disease manifestations. Similarly, proximity labeling approaches with RPL13 antibodies for immunoprecipitation can map the changing interactome of ribosomes in development and disease states, potentially revealing regulatory factors that interface with RPL13 to control specialized translation programs.

What considerations should be taken into account when using RPL13 as a reference gene or normalization control?

For studies involving cellular stress, ribosome biogenesis, or translation regulation, RPL13 is particularly inappropriate as a reference gene since its expression may be directly affected by the experimental conditions. Similarly, in cancer studies, ribosomal proteins including RPL13 have been implicated as potential tumor suppressors , meaning their expression may change during carcinogenesis, compromising their utility as stable reference points.

When RPL13 is used for normalization, researchers should validate its expression stability under the specific experimental conditions being studied. This validation should involve comparing multiple reference genes and using algorithms such as geNorm, NormFinder, or BestKeeper to select the most stable options. Ideally, a panel of multiple reference genes, rather than RPL13 alone, should be used for normalization to improve reliability.

For protein-level normalization in Western blotting, total protein normalization methods (such as Ponceau S staining or stain-free technology) generally provide more reliable alternatives to specific protein loading controls like RPL13, particularly in studies where ribosome biogenesis or translation may be affected. If RPL13 antibodies are used for normalization, careful validation of consistent expression across all experimental conditions is essential.

How might RPL13 antibodies contribute to understanding specialized ribosomes and their roles in development?

The concept of specialized ribosomes—ribosomes with distinct compositions that preferentially translate specific subsets of mRNAs—represents an emerging frontier in translation research, and RPL13 antibodies can play a crucial role in exploring this phenomenon. The association of RPL13 variants with spondyloepimetaphyseal dysplasia, characterized by specific skeletal abnormalities rather than broad multi-system effects , supports the hypothesis that RPL13 may contribute to specialized translation in bone development. RPL13 antibodies can enable detailed mapping of RPL13 expression across different tissues and developmental stages through immunohistochemistry and immunofluorescence techniques, potentially revealing patterns that correlate with specialized translation programs.

By combining RPL13 immunoprecipitation with ribosome profiling or RNA sequencing, researchers can identify mRNAs associated with RPL13-containing ribosomes in different cellular contexts. This approach could reveal whether wild-type versus variant RPL13 proteins associate with distinct mRNA populations, particularly in chondrocytes and osteoblasts where RPL13 is highly expressed . Such findings would provide direct evidence for specialized ribosome function in tissue-specific development.

Proximity labeling approaches using RPL13 antibodies could map tissue-specific or developmental stage-specific interactions between RPL13 and other ribosomal proteins or regulatory factors. These interaction networks might explain how seemingly ubiquitous ribosomal components can contribute to specialized functions. Moreover, in situ hybridization combined with immunofluorescence using RPL13 antibodies could visualize the co-localization of specific mRNAs with RPL13-containing ribosomes in developing tissues, providing spatial context to specialized translation events.

As technologies for studying translation dynamics in living systems advance, RPL13 antibodies or antibody-derived tools (such as nanobodies or intrabodies) could enable real-time visualization of ribosome behavior during development, potentially revealing how specialized ribosomes contribute to the precise spatiotemporal control of protein synthesis required for proper tissue formation.

What emerging technologies might enhance the utility of RPL13 antibodies in translational research?

Emerging technologies are poised to expand the applications of RPL13 antibodies in investigating fundamental questions about ribosome biology and translation regulation. Cryo-electron microscopy combined with gold-labeled RPL13 antibodies could provide detailed structural insights into the integration of wild-type versus variant RPL13 proteins within the ribosome, potentially revealing subtle conformational changes that affect ribosome function. This approach could complement the computational modeling that has already suggested how the 18-amino acid insertion in RPL13 variants might disrupt interactions with ribosomal RNA .

Single-molecule imaging techniques using fluorescently labeled RPL13 antibody fragments could track individual ribosomes during translation, potentially revealing differences in elongation rates or pause site recognition between ribosomes containing wild-type versus variant RPL13. This could provide mechanistic insights into how seemingly subtle alterations in ribosome composition might affect translation dynamics.

Mass spectrometry-based approaches, particularly selective reaction monitoring (SRM) or parallel reaction monitoring (PRM) using RPL13-specific peptides, could enable precise quantification of wild-type versus variant RPL13 proteins in different tissues or cellular compartments. This would be particularly valuable for studying conditions like spondyloepimetaphyseal dysplasia, where the ratio of wild-type to variant protein might influence disease severity.

CRISPR-based approaches for endogenous tagging of RPL13, combined with proximity labeling techniques and immunoprecipitation with RPL13 antibodies, could reveal dynamic interaction networks in different cellular contexts. This might identify tissue-specific cofactors that interact with RPL13 to regulate specialized translation programs.

Advances in spatial transcriptomics and proteomics could be integrated with RPL13 immunodetection to map the spatial distribution of RPL13-containing ribosomes relative to their substrate mRNAs and synthesized proteins. This would provide unprecedented insights into how translation is spatially regulated during development, potentially explaining why mutations in ubiquitous proteins like RPL13 can have such tissue-specific effects.